Efficacy and safety of ustekinumab in patients with psoriasis and psoriatic arthritis
Ustekinumab is a fully human monoclonal immunoglobulin G1 antibody that binds specifically to the p40 subunit of IL-12 and IL-23 that participate in the pathogenesis of different autoim- mune diseases. Efficacy and safety of ustekinumab were shown in the randomised controlled clinical trials in patients with psoriasis (PHOENIX-1 and PHOENIX-2) and psoriatic arthritis (PSUMMIT-1 and PSUMMIT-2). In clinical studies, ustekinumab alleviated signs and symptoms of psoriatic dsease, that is, skin plaques, arthritis, enthesitis, dactilytis, produced rapid, consistent and sustained effect, was well-tol- erated and safe, and showed low immunogenicity.